Dyne Therapeutics (DYN) Stock: Buy, Sell, or Hold?
DYN - Dyne Therapeutics, Inc. Common Stock
$15.77
-0.30 (-1.87%)
▼
5d:
+3.14%
30d:
-2.83%
90d:
-35.47%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 20, 2026 at $16.27 · last confirmed Oct 22, 2026
Strength: 8.2/10
Get Alerted When DYN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DYN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DYN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DYN is currently trading at $15.77, which is considered fair relative to its 30-day fair value range of $15.28 to $17.18.
Technical Outlook: Technically, DYN is in a downtrend. Immediate support is located at $14.13, while resistance sits at $17.31.
Market Sentiment: DYN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $35.73 (+126.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DYN is in a downtrend. Immediate support is located at $14.13, while resistance sits at $17.31.
Market Sentiment: DYN scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $35.73 (+126.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$15.28 -
$17.18
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 126.6% below Wall St target ($35.73)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$15.28 -
$17.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$14.13
Resistance Level
$17.31
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.73
Wall Street Target
$35.73
(+126.6%)
Share & Embed Analysis
Last updated: October 23, 2026 4:37 AM ET
Data refreshes hourly during market hours. Next update: 5:37 AM
Data refreshes hourly during market hours. Next update: 5:37 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DYN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 61 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
23 analysts |
$86 | 66 BUY |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
Advanced DYN Option Strategies
Professional options setups generated by AI based on today's DYN price and gamma walls.